KLOW

KLOW is not a compound. It is a formulated blend of four separate peptides presented in a single vial: BPC-157, GHK-Cu, TB-500 and KPV. Three of those are cataloged individually by VaultLabs and have their own monographs; KPV is the C-terminal tripeptide fragment Lys-Pro-Val of α-melanocyte-stimulating hormone, studied in its own right in inflammation-signalling research.

The distinction between a compound and a blend matters more than it might appear. A single substance has a CAS registry number, a molecular formula, a defined mass and a meaningful purity percentage. A four-component mixture has none of those things as a whole. Suppliers that publish a CAS number or a single purity figure for a blend are, at best, describing one component and implying it covers all of them.

VaultLabs therefore lists no CAS number for KLOW. That is a deliberate accuracy decision rather than missing data, consistent with how the catalog handles other multi-component materials.

For a composite material, the analytically meaningful questions are different from those for a single peptide. Are all four named components actually present? In what ratio? Is each one identifiable against its own reference standard? A chromatogram of a four-peptide mixture should resolve four species, and a certificate should let you connect each to a component.

A laboratory intending to draw conclusions about any individual component is almost always better served by ordering that component separately, where the certificate describes one substance unambiguously. Blends are appropriate where the combination itself is the object of study.

It is also worth noting that the published literature for each constituent was generated using that constituent alone. There is no body of work establishing how these four behave together, and combining literature from four separate sources to describe a mixture is not a sound inference.

A mixture inherits the strictest handling requirement of any component, and it does so silently. GHK-Cu contributes a metal complex that is sensitive to chelating buffer components and to pH. TB-500 contributes a short fragment that is prone to oxidation once a vial is open. BPC-157 and KPV contribute conventional peptide constraints on hydrolysis and freeze-thaw cycling.

The practical result is that any single condition tolerable for three of the four components can still degrade the fourth, and a chromatogram of the blend will not necessarily make that obvious unless the method resolves all four species cleanly. Stability determinations made for an individual peptide do not transfer to the blend.

Store sealed lyophilised vials at 2–8 °C, protected from light and humidity, and equilibrate to room temperature before opening. The presence of GHK-Cu means the blend contains a metal complex, so avoid chelating buffer components; the presence of TB-500 and BPC-157 means the usual peptide handling constraints on freeze-thaw cycling and open-vial time apply.

Two of the named components — BPC-157 and TB-500 — are prohibited in sport under the World Anti-Doping Agency list. A laboratory connected to athlete populations or testing programmes should treat the blend as carrying those same constraints.

KLOW is not an approved medicine in any jurisdiction and is not supplied for human or veterinary use. Orders are accepted against a research-use declaration retained in the order record.

Multi-component reconstitution protocols

Blend stability documentation

Comparative single-vs-blend analytical workflows

Inventory simplification for multi-pathway model labs

2–8 °C (lyophilized, sealed)

2–8 °C sealed; component-sensitive — follow product page and batch COA notes.

Multi-component lyophilized blends require component-level COA review and validated reconstitution procedures — do not assume single-peptide handling protocols apply unchanged.